The Janssen Pharmaceutical Cos. of Johnson & Johnson reported positive results from the first of its pivotal trials for Tremfya (guselkumab) in inflammatory bowel disease (IBD) at Digestive Disease Week (DDW) on 9 May, setting the interleukin-23 inhibitor on pace to compete with the two frontrunners in the drug class in the treatment of ulcerative colitis (UC).
First Phase III IBD Trial Reads Out Positive For Janssen’s Tremfya
Data From More Studies Expected Later This Year
The IL-23 inhibitor, entering an increasingly competitive space, posted significant results at Digestive Disease Week from the Phase IIb/III QUASAR induction study in ulcerative colitis.
